Get the Stockscreener App
41.46
0.48%
-0.20
Xoma Royalty Corp stock is traded at $41.46, with a volume of 66,176.
It is down -0.48% in the last 24 hours and up +22.84% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
See More
Previous Close:
$41.66
Open:
$41.75
24h Volume:
66,176
Relative Volume:
0.28
Market Cap:
$502.89M
Revenue:
$52.15M
Net Income/Loss:
$24.35M
P/E Ratio:
28.51
EPS:
1.4544
Net Cash Flow:
$-17.93M
1W Performance:
+1.15%
1M Performance:
+22.84%
6M Performance:
+21.69%
1Y Performance:
+79.95%
1-Day Range:
$41.40
$41.75
1-Week Range:
$40.61
$41.85
52-Week Range:
$22.29
$42.81
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
41.46 | 505.31M | 52.15M | 24.35M | -17.93M | 1.4544 |
VRTX
Vertex Pharmaceuticals Inc
|
425.07 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.35 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
810.48 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.50 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.66 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday - Sahm
[SCHEDULE 13G] XOMA Royalty Corp Passive Investment Disclosure (>5%) - Stock Titan
H.C. Wainwright cuts XOMA stock rating on Ligand acquisition - Investing.com
HC Wainwright & Co. downgrades XOMA Royalty (XOMA) - MSN
BVF group backs XOMA Royalty Corp (XOMA) merger with 21.4% locked-up stake - Stock Titan
LGND: XOMA Buy Adds 100+ Assets - Yahoo Finance
XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm - GlobeNewswire
XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm - GlobeNewswire Inc.
Ligand to acquire XOMA Royalty - The Pharma Letter
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last? - Yahoo Finance
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - MarketBeat
BlackRock (NASDAQ: XOMA) reports 5.4% stake in XOMA Royalty Corp - Stock Titan
XOMA (XOMA) closes Generation Bio acquisition, details cash-plus-CVR terms and LNP assets - Stock Titan
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
HC Wainwright & Co. maintains XOMA Royalty (XOMA) buy recommendation - MSN
Promising Biotech Stocks To Watch TodayApril 27th - MarketBeat
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
Ligand Is Buying Xoma Royalty For $739 Million In Cash - Finimize
Ligand Pharmaceuticals Incorporated entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $470 million from BVF Partners L.P. and others. - marketscreener.com
Ademi LLP Investigates XOMA for Possible Violations - Intellectia AI
Xoma Royalty Corp - Reuters
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
Ademi LLP Investigates Whether XOMA Royalty Corporation Is Obtaining a Fair Price for Public Shareholders - Moomoo
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal - Stock Titan
Ligand Pharmaceuticals buying Xoma Royalty for $739 million - Yahoo Finance
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million, Expanding Biopharma Royalty Portfolio and Boosting 2026 EPS Guidance - Minichart
XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs - TradingView
XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders - Business Wire
Ligand to buy XOMA Royalty (Nasdaq: XOMA) in $739M cash and CVR deal - Stock Titan
XOMA Royalty: Transaction Is Expected to Close in the 3Q of 2026 >XOMA - Moomoo
Ligand to acquire XOMA Royalty for $739 million in cash - Investing.com
Ligand to acquire XOMA Royalty for $739 million in cash By Investing.com - Investing.com Australia
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator - The Manila Times
XOMA Stock Price, Quote & Chart | XOMA ROYALTY CORPORATION (NASDAQ:XOMA) - ChartMill
XOMA Royalty (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
XOMA (XOMA) CFO converts 11,538 Performance Stock Units into common shares - Stock Titan
XOMA (XOMA) legal chief converts 3,370 PSUs into common shares - Stock Titan
XOMA (XOMA) CEO Owen Hughes exercises 10,568 PSUs and updates holdings - Stock Titan
XOMA (XOMA) CIO boosts direct common holdings via 3,737 PSU conversion - Stock Titan
XOMA Technical Analysis & Stock Price Forecast - Intellectia AI
XOMA ROYALTY CORPXOMA 8 3/8 PERP (NASDAQ:XOMAO) Checks All Eight Boxes in Navellier’s Little Book Growth Screen - ChartMill
XOMA (XOMA) CFO exercises 4,000 PSUs, 1,632 shares withheld for taxes - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
XOMA Corp8.375% DP PFD B declares $0.5234 dividend - MSN
Published on: 2026-04-13 23:42:40 - baoquankhu1.vn
XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World
GBIO SEC FilingsGeneration Bio Co. 10-K, 10-Q, 8-K Forms - Stock Titan
Retail Surge: Is now the right time to enter XOMA Royalty Corporation2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):